Clinical trial • Phase IV • Other

Mepivacaine hydrochloride for Postoperative pain

Phase IV trial of Mepivacaine hydrochloride for Postoperative pain.

Overview

Trial Therapeutic Area
Other
Trial Disease
Postoperative pain
Trial Stage
Phase IV
Drug Modality
Small molecule
Paediatric Trial
Yes

Key dates

Initial CTIS Submission Date
21-11-2023
First CTIS Authorization Date
12-02-2024

Trial design

Randomised, open-label, experimental arm: locoregional analgesia + general anaesthesia; control arm: general anaesthesia alone. Phase IV trial in France.

Randomised
Yes
Open Label
Yes
Comparator
Experimental arm: Locoregional Analgesia + general anaesthesia; Control arm: General anaesthesia alone.
Target Sample Size
222
Trial Duration For Participant
365

Eligibility

Recruits 222 paediatric patients.

Vulnerable Population
Children aged ≥5 years and <15 years 3 months are the trial population. Informed and signed consent of the patient and one of the two holders of parental authority is required; age-specific subject information and informed consent forms are provided (SIS and ICF 5-10y, SIS and ICF 10-15y) and a parent ICF is available.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 5 years and < 15 years and 3 month"}
  • {"criterion_text":"- Indication for surgical treatment of a fracture by osteosynthesis"}
  • {"criterion_text":"- Patient affiliated to the social security system"}
  • {"criterion_text":"- Informed and signed consent of patient and one of the two holders of parental authority"}
  • {"criterion_text":"- Conscious patient (Glasgow score =15)"}
  • {"criterion_text":"- Patient can give a verbal assessment of their pain"}

Exclusion criteria

  • {"criterion_text":"- Refusal to participate by one of the two holders of parental authority or by the child"}
  • {"criterion_text":"- atrioventricular conduction disorders"}
  • {"criterion_text":"- Sensory neurological deficit of the operated limb on preoperative examination"}
  • {"criterion_text":"- Ischemia of the operated limb on preoperative examination"}
  • {"criterion_text":"- Polytrauma patient"}
  • {"criterion_text":"- Known allergy to Mepivacaine"}
  • {"criterion_text":"- Patient included in a category 1 interventional clinical trial of analgesic therapy"}
  • {"criterion_text":"- Patient on anticoagulant drugs"}
  • {"criterion_text":"- Epilepsy not controlled by a treatment"}
  • {"criterion_text":"- Porphyria"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Measurement of pain by a Numerical Rating Scale (NRS) 3 months after pediatric orthopedic trauma surgery","definition_or_measurement_approach":"Pain measured by Numerical Rating Scale (NRS) at 3 months after pediatric orthopedic trauma surgery."}

Secondary endpoints

  • {"endpoint_text":"- Response score to DN4 neuropathic pain screening questionnaire ≥4/10 at 3, 6 and 12 months.","definition_or_measurement_approach":"DN4 neuropathic pain screening questionnaire; response defined as DN4 score ≥4/10 measured at 3, 6 and 12 months."}
  • {"endpoint_text":"- 1st EN score for immediate post-operative care in the Post-Interventional Monitoring Room","definition_or_measurement_approach":"Immediate postoperative pain assessed by first Numerical Rating Scale (EN) score in the Post-Interventional Monitoring Room."}
  • {"endpoint_text":"- Presence of pain assessed by numerical scale >3/10 at 6 and 12 months post-surgery","definition_or_measurement_approach":"Presence of pain defined as numerical scale score >3/10 measured at 6 and 12 months post-surgery."}
  • {"endpoint_text":"- The number of patients experiencing at least one episode of nausea and one episode of vomiting in the Post-Interventional Monitoring Room.","definition_or_measurement_approach":"Count of patients with at least one episode of nausea and at least one episode of vomiting in the Post-Interventional Monitoring Room."}
  • {"endpoint_text":"- Duration in minutes of monitoring in the Post-Interventional Monitoring Room","definition_or_measurement_approach":"Monitoring duration measured in minutes in the Post-Interventional Monitoring Room."}
  • {"endpoint_text":"- The dose of intravenous opiates received intraoperatively, the dose of intravenous opiates titrated in the Post-Interventional Monitoring Room and the dose of opiates received in the hospital ward during the first 24 hours postoperatively.","definition_or_measurement_approach":"Quantification of opiate doses administered intraoperatively, in the Post-Interventional Monitoring Room (titrated), and in the ward during first 24 hours post-op."}
  • {"endpoint_text":"- The dose of IV morphine received in the ICU.","definition_or_measurement_approach":"Dose of intravenous morphine received in the Post-Interventional Monitoring Room / ICU measured (total dose)."}

Recruitment

Planned Sample Size
222
Recruitment Window Months
60
Consent Approach
Informed and signed consent required from the patient and one of the two holders of parental authority; age-specific information and consent forms available (SIS and ICF 5-10y, SIS and ICF 10-15y) and parent ICF.

Geography

Total Number Of Sites
1
Total Number Of Participants
222

France

Earliest CTIS Part Ii Submission Date
10-01-2024
Latest Decision Or Authorization Date
12-03-2026
Processing Time Days
792
Number Of Sites
1
Number Of Participants
222

Sites

Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
ANESTHESIE
Contact Person Name
Benoît LESVIER
Contact Person Email
benoit.lesvier@chu-nantes.fr

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Universitaire De Nantes
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Third parties

  • {"country":"","full_name":"Fondation APICIL","duties_or_roles":"","organisation_type":""}
  • {"country":"","full_name":"CHU Nantes - Appel d'offre interne","duties_or_roles":"","organisation_type":""}

Investigational products

Investigational Product Name
CARBOCAINE 10 mg/ml, solution injectable
Active Substance
Mepivacaine hydrochloride
Modality
Small molecule
Routes Of Administration
Perineural use (solution for injection)
Route
Perineural
Authorisation Status
Authorised (marketing authorisation present)
Maximum Dose
5 mg/kg
Combination Treatment
Yes

Related trials

Other published trials that may interest you.